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Background: Acquired angioedema is a rare but recognized manifestation of lymphoproliferative disorders due to
deficiency in C1 esterase inhibitor. Normal level of C1 esterase inhibitor proteins in association with angioedema
due to lymphoproliferative disease is a rare and an uncommon finding caused by antibodies produced from the
underlying disease. Antibodies cause inactivation of C1 esterase inhibitor, thus resulting in C1 esterase inhibitor
dysfunction despite of normal quantity of C1 esterase inhibitor.
Case presentation: A 50-year-old Sri Lankan male presented with first episode of angioedema without any family
history. Physical examination revealed mild pallor with swelling of tongue, lips and perioral region. On investigations,
erythrocyte sedimentation rate was persistently high and bone marrow with immunohistochemistry revealed
infiltration with B-cell type low grade non-Hodgkin lymphoma. Computed tomography scan of the chest and
abdomen showed paratracheal and subcarinal lymphadenopathy and splenomegaly, with the findings being
compatible with lymphoma. He had normal C1 esterase inhibitor protein level with reduced activity and low C1q, C4
levels indicating antibodies against C1 esterase inhibitor causing dysfunctional C1 esterase inhibitor.
Conclusion: Adult onset angioedema should prompt physicians to suspect underlying lymphoproliferative disorder
despite of C1 esterase inhibitor protein level being normal. Though uncommon, presence of antibodies against C1
esterase inhibitor secondary to lymphoproliferative disorder should be considered in the presence of normal C1
esterase inhibitor protein levels with low functional capacity in the background of acquired angioedema.
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B-cell non-Hodgkin lymphomaBackground
Angioedema is a life-threatening condition described as a
transient, non-pruritic, non-pitting localized swelling of cu-
taneous and mucosal tissues. It often presents with facial,
tongue, laryngeal or abdominal edema [1,2]. Several forms
of angioedema are described; hereditary, acquired, allergen
associated and idiopathic. Acquired angioedema is reported
as a rare clinical manifestation [2-4]. However it is a well-
recognized phenomenon associated with non-Hodgkin
lymphoma (NHL) [5-7], commonly B cell type [1,8] as
well as other lymphoproliferative disorders (lymphosar-
coma, chronic lymphocytic leukemia, Waldenstrom’s* Correspondence: sonaligunatilake@gmail.com
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article, unless otherwise stated.macroglobulinemia and multiple myeloma [4,9]). Angio-
edema usually precede the diagnosis of lymphoprolifera-
tive disease or may occur several years after the diagnosis
[5,10]. Described mechanisms of acquired angioedema are
either increased activation resulting consumption of C1
esterase inhibitor leading to reduced levels, commonly
seen in lymphoproliferative diseases [11] or antibodies
against C1esterase inhibitor as seen in autoimmune dis-
eases. We report a rare case where angioedema was the
first presentation of B-cell NHL. The C1 esterase inhibitor
(C1-INH) protein levels were normal with decreased level
of activity due to antibodies against C1 esterase inhibitor
protein causing dysfunctional C1-INH, an uncommon
finding in lymphoproliferative diseases.BioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Contrast enhanced computed tomography scan of
chest showing sub-carinal lymphadenopathy. (Arrow indicates
sub-carinal lymphadenopathy).
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A 50-year-old previously well Sri Lankan male patient pre-
sented to the Oro-Maxillo-Facial (OMF) surgical unit and
then referred to the general medical unit with the com-
plaint of sudden onset swelling of lips, tongue and face for
24 hours. It was painless but progressive over the day.
There was no peri-orbital swelling or peripheral edema.
He had not experienced dyspnea, wheezing, abdominal
pain or body itching. There were no identifiable precipitat-
ing factors attributing to angioedema. He denied any his-
tory of atopy or allergy. It was the first episode of this
nature that he had experienced in his life and there were
no previous documented cases of angioedema in his fam-
ily. He was not on any short or long term medication. On
detailed history, patient had experienced loss of appetite
and loss of weight (8 kg) over the past 3 months but de-
nied fever, night sweats, chronic cough, joint swelling, oral
ulcers and rashes.
On examination, his weight was 49 kg, swelling of the
tongue, lips and perioral region were noted. There was
mild pallor without icterus but no lymphadenopathy,
hepato-splenomegaly or abdominal masses. There were
no dental caries, oral ulcers, joint swelling, rashes or bone
tenderness. He had a regular pulse with blood pressure of
120/80 mmHg. Respiratory, neurological and loco-motor
system examination were unremarkable.
Subsequent investigations revealed hemoglobin of
10.3 g/dL, white cell count of 5.52×103/μL (neutrophils –
38.6%, lymphocytes – 45%, monocytes-14%, eosinophils-
1.3% and basophils-0.7%) and a platelet count of
207×103/μL. Blood picture showed normochromic nor-
mocytic red cells with marked rouleaux formation, total
white cell count was normal with lymphocytic predom-
inance and normal platelets. No atypical cells were seen.
Erythrocyte sedimentation rate was 130 mm in 1st hour.
Serum lactate dehydrogenase level was 960 IU/L (nor-
mal: 100–300 IU/L), C-reactive protein, liver profile and
renal profile were normal. Mantoux test was negative.
Serology for anti-nuclear antibodies (ANA), retroviral
studies, Venereal disease research laboratory (VDRL)
test, hepatitis B surface antigen, hepatitis C antibodies,
Epstein-Barr virus and cytomegalovirus antibodies were
negative.
C1 esterase inhibitor protein level was 23.71 mg/dl (15-
35 mg/dL; measured by radio immunediffusion technique)
and the functional percentage of C1 esterase inhibitor was
15% (normal >67%, equivocal 41-67%, abnormal <41%) at
the time of angioedema. The serum compliment levels were
as follows; C3 level – 110 mg/dL (75-165 mg/dL), C4 –
2 mg/dl (14-54 mg/dL) and C1q – 26% (75 -125%).
Bone marrow showed marked hyper cellularity with dif-
fuse infiltration of homogenously mature lymphoid cells
(70%). Blasts cells were 1% of marrow nucleated cells.
Erythropoiesis, granulopoiesis and megakaryopoiesis weremarkedly suppressed. Features were compatible with bone
marrow infiltration by low grade non-Hodgkin lymphoma
(NHL). Immunohistochemistry of the bone marrow re-
vealed CD20 positivity with negative results for CD10,
CD3, CD138, CD23 and terminal deoxynucleotidyl trans-
ferase (TdT) markers, indicating compatibility with B-cell
non-Hodgkin lymphoma. Soluble interleukin 2 receptor
levels were not carried out due to unavailability of the la-
boratory facilities.
Electrocardiogram showed sinus rhythm and chest roent-
genogram was normal. Ultrasound scan of the abdomen
showed mild splenomegaly (15 cm). Contrast enhanced
computed tomography (CT) scan of the chest, abdomen
and pelvis showed right pretracheal and subcarinal lymph-
adenopathy with mild splenomegaly compatible with the
diagnosis of lymphoma (Figure 1).
Patient was diagnosed to have B cell NHL with an epi-
sode of acquired angioedema on presentation. He did
not have any life threatening episodes of angioedema but
was managed initially with steroids and danazole, to
which he responded slowly but completely and started
on chemotherapy for the management of NHL. He is on
oncology clinic follow-up and he did not develop any
further episodes of angioedema thereafter up to 6 months
follow-up after starting chemotherapy. Subsequent mea-
surements of complement levels including C4 and C1q
were within normal limits.
Discussion
Angioedema is a life-threatening condition which is be-
ing described as a transient, non-pruritic, non-pitting
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which often involves upper respiratory tract or gastro-
intestinal tract [1,2]. Neurological and cardiac involve-
ment had also been described [4,12]. There are several
subtypes, (1) Hereditary, (2) Acquired, (3) Allergen asso-
ciated and (4) Idiopathic [1].
Acquired angioedema shares many features similar to
hereditary angioedema but differs by the absence of a
positive family history of angioedema and late onset
presentation, usually after the age of 40 [1]. It was first
described by Caldwell in 1972 [13] and is a rare condi-
tion with an estimated prevalence of 1:100 000 to 1:150
000 [14]. Pathophysiology reveals that when the C1 es-
terase inhibitor protein level is decreased due to exces-
sive consumption, or dysfunctional due to the presence
of antibodies against C1-INH (although C1-INH protein
level is normal), inhibition of the complements and the
kinin system is defective. This results in an abnormal
exaggerated response in the compliment pathway caus-
ing increased vascular permeability (by mediators such
as bradykinin) causing angioedema. Two types of ac-
quired angioedema is described in the literature.
Type I - Low level of C1-INH (<30% of normal); seen in
lymphoproliferative disease or paraneoplastic syndromes.
Type II - Antibodies against C1-INH present; seen in
connective tissue disease.
Acquired angioedema (AAE) is a rare phenomenon
in association with lymphoproliferative disorders. As-
sociated lymphoproliferative disorders range from
monoclonal gammopathy of unknown significance –
MGUS (35%) to non-Hodgkin lymphoma (20%) [1,10].
B-cell non-Hodgkin lymphoma is the commonest of
lymphoma to give rise to angioedema, especially recur-
rent angioedema [1,5-8], and angioedema may precede
or follow the diagnosis of NHL [5,10,15]. Few cases are
reported with acquired angioedema being the first
manifestation of NHL [5].
Pathogenesis of AAE in B-cell NHL is incompletely
understood [16] but suggests activation of classical com-
plement pathway from immune complexes or monoclo-
nal antibodies produced by the tumor tissue leading to
consumption of C1-INH. Thus serum C1, C1q, C2, C4
level and C1-INH protein levels will be lower than the
normal (AAE Type I). This mechanism is well described
and reported in many case reports [2-4,6,8,17]. Although
not common, a monoclonal antibody that inactivates the
C1-INH leading to non-functional C1-INH resulting in
angioedema had also been reported [15,17,18]. Normally
C1-INH is cleaved by the targeted proteases. Cleaved
products bind to the proteases in the complement and
kinin pathways irreversibly and render them inactive. In
the presence of inhibitor antibodies to C1-INH, still C1-
INH is cleaved but cannot bind to the proteases to make
them inactive, thus the proteases continue to function.This results in uncontrolled activation of complement
pathway and production of bradykinin leading to angio-
edema. It gives rise to normal C1-INH protein levels with
a defective function and low C1q and C4 levels (as a result
of activation of classical complement pathway and exces-
sive consumption of the compliment components) as well
as antibodies against C1-INH can be identified (produced
by the lymphoma cells). This mechanism (AAE Type II) is
well described in relation to connective tissue diseases
causing acquired angioedema, but less commonly with
lymphoproliferative diseases. Gaur et al. had reported a
case with lymphoma associated angioedema with normal
C1-INH and C4 levels, in which the mechanism was not
well understood.
The patient in this case report was diagnosed to have B-
cell NHL following investigations for a single episode of
acquired angioedema, which is a rare presentation. The
underlying cause for an acquired angioedema should be
aggressively pursued in such a patient to exclude an
underlying lymphoproliferative disease. He had low C1q
and C4 levels, indicating an acquired form of angioedema
with normal C1-INH protein levels and low functional
C1-INH (due to antibody mediated defective function of
C1-INH), which is less commonly described in relation to
lymphoproliferative disorders in literature. The antibodies
against C1-INH and CH50 level were not carried out due
to lack of laboratory facilities but low levels of C4 and
functional C1-INH irrespective of normal level of C1-INH
proteins supported the diagnosis.
Conclusion
This rare case of acquired angioedema as the first mani-
festation of non-Hodgkin lymphoma highlights the im-
portance of having a high degree of suspicion to exclude
occult malignancies or underlying disease in patients with
adult onset angioedema. Although rare, the possibility of
auto antibodies inactivating C1-INH (acquired angio-
edema type II) should be appreciated in the presence of
lymphoma, resulting in acquired angioedema with normal
C1 esterase protein levels.
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